What we do Nephrocare Health Services Ltd operates Asia's largest dialysis network, offering comprehensive dialysis care including in-clinic, home, and mobile dialysis, supported by pharmacy services. |
Founded in 2,009 |
Market share Holds over 50% market share in India's organized dialysis segment; third largest in the Philippines. |
Problem solved Provides accessible, affordable, and quality dialysis care to chronic kidney disease patients across India and international markets. |
Top clients or who we serve Serves 36,000+ dialysis patients through 520+ clinics in India and abroad; B2C patients requiring ongoing dialysis treatment. |
Key management Vikram Vuppala (Chairman & MD), Rohit Singh (Group CEO), Prashant Goenka (Group CFO). |
Our journey and innovations Started in 2010 with 1 clinic, pioneered PPP model in 2012, acquired DaVita India in 2018, expanded internationally since 2020 with multiple acquisitions. |
Where we operate India, Philippines, Uzbekistan, Nepal, Kingdom of Saudi Arabia. |
Top products or what we offer Dialysis services including haemodialysis, home haemodialysis, mobile dialysis, supported by pharmacy and wellness programs. |
Top brands NephroPlus - Asia's largest dialysis chain; operates flagship clinics like world's largest dialysis center in Tashkent with 165 beds. |
Raw materials needed Dialysis consumables, medical equipment, pharmaceuticals related to dialysis treatment. |
Raw materials supplier Direct manufacturer relationships and in-house contract manufacturing to optimize costs and supply chain timelines. |
Recurring vs cyclical contribution Revenue is largely recurring, driven by regular dialysis treatments multiple times weekly for chronic patients. |
Our industry position Market leader in Indian organized dialysis sector; third largest global network by treatment volumes in key international markets. |
Financial highlights FY25 revenue ₹755.8 Cr, Net profit ₹67.1 Cr; 31% CAGR in revenue over 3 years; 23.9% adjusted EBITDA margin in 9M FY26. |
Geographical revenue split About 59% revenue from India; 41% from international operations including Philippines and Uzbekistan. |
Order book - |
Whats driving growth Rising CKD due to diabetes and hypertension, under-penetrated markets, expansions and acquisitions, and higher revenue per treatment in international markets. |
Our future plans Expand footprint in current markets, enter new geographies, scale PPP models, introduce tech-led healthcare innovations. |
Our green promise - |
Our people and values Patient-centric care philosophy; invests in training through Enpidia Academy; emphasizes clinical quality and community engagement. |
Key challenges ahead Managing integration of acquisitions, regulatory changes, cost control while scaling internationally under varied healthcare policies. |
Interesting facts Co-founder Kamal Shah is a dialysis patient for 28+ years, author of a book on dialysis journey, inspiring patient-centric culture. |
Risks and strategy Risk from regulatory shifts and competition mitigated by protocol-driven care, technology adoption, and diversified geographic presence. |
